Pain syndrome in patients receiving chronic program dialysis

A.P. Spasova, O.Yu. Barysheva, V.V. Maltsev

Medical Institution of Petrozavodsk State University, Petrozavodsk

For correspondence: Arina P. Spasova, Candidate of Medical Science, Assistant Professor of Chair of X-Ray diagnostic and X-Ray treatment with course of Critical And Respiratory Medicine of Medical Institution of Petrozavodsk State University, Petrozavodsk; e-mail:

For citation: Spasova AP, Barysheva OYu, Maltsev VV. Pain syndrome in patients receiving chronic program dialysis. Alexander Saltanov Intensive Care Herald. 2019;1:52–64.

DOI: 10.21320/1818-474X-2019-1-52-64

The review analyzes the prevalence of chronic pain syndromes in patients on chronic hemodialysis program. The features of the formation of pain are discussed, both during the hemodialysis procedure and in the interdialytic period. We consider methods for assessing chronic pain syndrome, taking into account its specifics, as well as the basic principles of therapy.

Keywords: chronic pain, acute pain, hemodialysis

Received: 31.01.2019


  1. Davison S.N., Jhangri G.S. Impact of pain and symptom burden on the Health-Related Quality of Life of haemodialysis patients. Journal of pain and symptom management. 2010; 39(3): 477–485. DOI: 10.1016/j.jpainsymman.2009.08.008
  2. Gamondi C., Galli N., Schonholzer C., et al. Frequency and severity of pain and symptom distress among patients with chronic kidney disease receiving dialysis. Swiss Medical Weekly. 2013; 143: w13750. DOI: 10.4414/smw.2013.13750
  3. Harris T.J, Nazir R., Khetpal P., et al. Pain, sleep disturbance and survival in haemodialysis patients. Nehpr Dial and Transpl. 2012; 27(2): 758–765. DOI: 10.1093/ndt/gfr355
  4. Brkovic T., Burilovic E., Puljak L. Prevalence and severity of pain in adult end-stage renal disease patients on chronic intermittent hemodialysis: a systematic review. Patient Preference and Adherence. 2016; 10: 1131–1150. DOI: 10.2147/PPA.S103927
  5. Zyga S., Alikari V., Sachlas A., et al. Assessment of fatigue in End-Stage Renal Disease patients undergoing haemodialysis: prevalence and associated factors. Medical Archives. 2015; 69: 376–380. DOI: 10.5455/medarh.2015.69.376–380
  6. Weisbord S.D., Carmody S.S., Bruns F.J., et al. Symptom burden, quality of life, advance care planing and the potential value of pallaitive care in severely ill haemodialysis patients. Nephrol Dial Transplant. 2003; 18(7): 1345–1352.
  7. Davison S.N. Pain in hemodialysis patients: prevalence, cause, severity and management. Am. J. Kidney Dis. 2003; 42(6): 1239–1247.
  8. Claxton R.N., Blackhall L., Weisbord S.D., Holley J.L. Undertreatment of symptoms in patients on maintenance hemodialysis. J Pain Symptom Manage. 2010; 39(2): 211–218. DOI: 10.1016/j.jpainsymman.2009.07.003
  9. Weisbord S.D., Fried L.F., Mor M.K., et al. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin. J. Am. Soc. Nephrol. 2007; 2(5): 960–967. DOI: 10.2215/CJN.00990207
  10. Cohen S.D., Patel S.S., Khetpal P., et al. Pain, sleep disturbance, and quality of life in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2007; 2(5): 919–925. DOI: 10.2215/CJN.00820207
  11. Rodriguez Calero M.A., Sánchez D.H., Navarro J.G., et al. Assessment and management of intra-dialysis pain] Evaluación y manejo del dolor intradiálisis. Rev Soc Esp Enferm Nefrol. 2006; 9(2): 65–70.
  12. Bailie G., Mason N., Bragg-Gresham J., et al. Analgesic prescription patterns among haemodialysis patients in the DOPPS: Potential for underprescription. Kidney International. 2004; 65(6): 2419–2425. DOI: 10.1111/j.1523-1755.2004.00658.x
  13. Wu J., Ginsberg J., Zhan M., et al. Chronic pain and analgesic use in CKD: implications for patient safety. Clinical Journal of American Society of Nephrology. 2015; 10(3): 435–442. DOI: 10.2215/CJN.06520714
  14. Williams A., Manias E. Balancing safety with effective pain control in patients with chronic kidney disease. J. Eval. Clin. Pract. 2007; 13(5): 820–822. DOI: 10.1111/j.1365-2753.2006.00744.x
  15. Feldman R., Berman N., Reid M.C., et al. Improving symptom management in hemodialysis patients: identifying barriers and future directions. Palliat. Med. 2013; 16: 1528–1533. DOI: 10.1089/jpm.2013.0176
  16. Aitken E., McLellan A., Glen J., et al. Pain resulting from arteriovenous fistulae: prevalence and impact. Clin. Nephrol. 2013; 80: 328–333. DOI: 10.5414/CN107917
  17. Tomasello S. Central nervous system medications, Semin Dial. 2010; 23(5): 469–72.
  18. Manley H.J., Cannella C.A., Bailie G.R., St Peter W.L. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis, Am. J. Kidney Dis. 2005; 46(4): 669–680. DOI: 10.1053/j.ajkd.2005.07.001
  19. Salisbury E.M., Game D.S., Al-Shakarchi I., et al. Changing practice to improve pain control for renal patients. Postgraduate Medical Journal. 2009; 85(999): 30–33. DOI: 10.1136/pgmj.2008.071191
  20. Goldstein D.A., Chui L.A., Massry S.G. Effect of parathyroid hormone and uremia on peripheral nerve calcium and motor nerve conduction velocity. Clin. Invest. 1978; 62(1): 88–93. DOI:10.1172/JCI109118
  21. Noordzij M., Boeschoten E.W., Bos W.J., et al. Disturbed mineral metabolism is associated with muscle and skin complaints in a prospective cohort of dialysis patients. Nephrol. Dial. Transplant. 2007; 22(10): 2944–2949. DOI: 10.1093/ndt/gfm319/
  22. Davison S.N., Koncicki H., Brennan F. Pain in chronic kidney disease: a scoping review. Semin Dial. 2014; 27(2): 188–204. DOI: 10.1111/sdi.12196
  23. Theofilou P. Psychiatric disorders in chronic periodic hemodialysis. Vima of Asklipiou. 2010; 9 (4): 420–440.
  24. Weisbord S.D., Fried L.F., Arnold R.M., et al. Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index. Pain Symptom Manage.2004; 27(3): 226–240. DOI: 10.1016/j.jpainsymman.2003.07.004
  25. Davison S.N., Jhangri G.S., Johnson J.A. Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients. Nephrol Dial Transplant. 2006; 21(11): 3189–3195. DOI: 10.1093/ndt/gfl380
  26. Hearn J., Higginson I.J. Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. Qual. Health Care. 1999; 8(4): 219–227. DOI: 10.1136/qshc.8.4.219
  27. Tamura M.K., Wadley V., Yaffe K. Kidney function and cognitive impairment in US adults: the Reasons for Geographic And Racial Differences in Stroke (REGARDS) Study. Am. J. Kidney Dis. 2008; 52(2): 227–234. DOI: 10.1053/j.ajkd.2008.05.004
  28. Murray A.M., Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv. Chronic Kidney Dis. 2008; 15(2): 123–32.
  29. Figueiredo A.E., Viegas A., Monteiro M., Poli-de-Figueiredo C.E. Research into pain perception with arteriovenous fistula (AVF) cannulation. J. Ren. Care. 2008; 34(4): 169–172. DOI: 10.1111/j.1755-6686.2008.00041.x
  30. Crespo R., Rivero M.F., Contreras M.D., Guisado C. Influence of bevel position of the needle on puncture pain in haemodialysis. EDTNA ERCA J. 1994; 20(4): 21–23.
  31. Figueiredo A.E., Viegas A., Monteiro M., Poli-de-Figueiredo C.E. Research into pain perception with arteriovenous fistula (AVF) cannulation. J. Ren. Care. 2008; 34(4): 169–172. DOI: 10.1111/j.1755-6686.2008.00041.x
  32. Bay W.H., Van Cleef S., Owens M. The hemodialysis access: preferences and concerns of patients, dialysis nurses and technicians, and physicians. Am. J. Nephrol. 1998; 18(5): 379–383. DOI: 10.1159/000013380
  33. Ferrans C.E., Powers M.J. Quality of life of hemodialysis patients. ANNA J. 1993; 20(5): 575–581; discussion 582.
  34. Grudzinski A., Mendelssohn D., Pierratos A., Nesrallah G. A systematic review of buttonhole cannulation practices and outcomes. Semin. Dial. 2013; 26(4): 465–475. DOI: 10.1111/sdi.12116
  35. Wong B., Muneer M., Wiebe N., et al. Buttonhole versus rope-ladder cannulation of arteriovenous fistulas for hemodialysis: a systematic review. Am. J. Kidney Dis. 2014; 64(6): 918–936. DOI: 10.1053/j.ajkd.2014.06.018
  36. Atkar R.K., MacRae J.M. The buttonhole technique for fistula cannulation: pros and cons. Curr. Opin. Nephrol. Hypertens. 2013; 22(6): 629–636. DOI: 10.1097/MNH.0b013e328365ae9e
  37. Wong B., Muneer M., Wiebe N., et al. Buttonhole versus rope-ladder cannulation of arteriovenous fistulas for hemodialysis: a systematic review. Am. J. Kidney Dis. 2014; 64(6): 918–936. DOI: 10.1053/j.ajkd.2014.06.018
  38. Çelik G..1, Özbek O., Yilmaz M.M., et al. Vapocoolant spray vs. Lidocaine/Prilocaine cream for reducing the pain of venipuncture in hemodialysis patients: a randomized, placebo-controlled crossover study. Int. J. Med. Sci. 2011; 8(7): 623–627.
  39. McPhail S. Hemodialysis needles can be pain free: use of a topical anesthetic cream. CAANT. 1992; 2(4): 19–20.
  40. Bana D.S., Yap A.U., Graham J.R. Headache during hemodialysis. Headache. 1972; 12(1): 1–14.
  41. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24(Suppl. 1): 9–160.
  42. Göksan B., Karaali-Savrun F., Ertan S., Savrun M. Hemodialysis-related headache. Cephalagia. 2004; 24(4): 284–287. DOI: 10.1111/j.1468-2982.2004.00668.x
  43. Antoniazzi A., Bigal M., Bordini C., Speciali J. Headache associated with dialysis: the Internation Headache Society criteria revisited. Cephalagia. 2003; 23(2): 146–149. DOI: 10.1046/j.1468-2982.2003.00510.x
  44. Goksel B.K., Torun D., Karaca S., et al. Is low blood magnesium level associated with hemodialysis headache? Headache. 2006; 46(1): 40–45. DOI: 10.1111/j.1526-4610.2006.00295.x
  45. Walters R.J., Fox N.C., Crum W.R., et al. Haemodialysis and Cerebral Oedema Nephron. 2001; 87(2): 143–147. DOI: 10.1159/000045903
  46. Antoniazzi A., Corrado A.P. Dialysis headache. Curr. Pain Headache Rep. 2007; 11(4): 297–303.
  47. Elshahawy Y., Sany D., Shawky S. Outcome of individualized dialysate sodium concentration for hemodialysis patients. Saudi J. Kidney Dis. Transpl. 2013; 2493): 507–513.
  48. Fang J., Huang C. Midodrine hydrochloride in patients on hemodialysis with chronic hypotension. Ren. Fail. 1996; 18(2): 253–260.
  49. Canzanello V.J., Burkart J.M. Hemodialysis-associated muscle cramps. Semin Dial. 1992; 5: 299.
  50. Levin N.W., Kupin W.L., Zasuwa G., Venkat K. Complications during hemodialysis in Clinical Dialysis. 2nd ed. Appleton and Lange. 1990; 172–201.
  51. Khajehdehi P., Mojerlou M., Behzadi S., and Rais-Jalali G.A. A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps. Nephrology Dialysis Transplantation. 2002; 16(7): 1448–1451.
  52. Lynch K.E., Feldman H.I., Berlin J.A., et al. Effects of L-carnitine on dialysis-related hypotension and muscle cramps: a meta-analysis. American Journal of Kidney Diseases. 2008; 52(5): 962–971. DOI: 10.1053/j.ajkd.2008.05.031
  53. Kelber J., Slatopolsky E., and Delmez J.A. Acute effects of different concentrations of dialysate magnesium during high efficiency dialysis. American Journal of Kidney Diseases. 1994; 24(3): 453–460.
  54. Ahsan M., Gupta M., Omar I. et al. Prevention of hemodialysis-related muscle cramps by intradialytic use of sequential compression devices: a report of four cases. Hemodialysis International. 2004; 8(3): 283–286. DOI: 10.1111/j.1492-7535.2004.01106.x
  55. Kahan M., Wilson L., Mailis-Gagnon A., Srivastava A. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. Can Fam Physician. 2011; 57(11): 1269–1276, 1419–1228.
  56. Dworkin R.H., O’Connor A.B., Audette J., et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010; 85(Suppl. 3): S3–14. DOI: 10.4065/mcp.2009.0649
  57. Barakzoy A.S., Moss A.H. Efficacy of the World Health Organization analgesic ladder to treat pain in end-stage renal disease. J. Am. Soc. Nephrol. 2006; 17(11): 3198–3203. DOI: 10.1681/ASN.2006050477
  58. Davison S.N. Chronic pain in end-stage renal disease. Adv. Chronic. Kidney Dis. 2005; 12(3): 326–334.
  59. Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Twenty four years of experience. Can. Fam. Physician. 2010; 56(6): 514–517.
  60. Bailie G.R., Mason N.A., Bragg-Gresham J.L., et al. Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for under prescription. Kidney Int. 2004; 65(6): 2419–2425. DOI: 10.1111/j.1523-1755.2004.00658.x
  61. Grubb N.G., Rudy D.W., Brater D.C., Hall S.D. Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a ‘futile cycle’ of elimination. Br. J. Clin. Pharmacol. 1999; 48(4): 494–500.
  62. Koncicki H.M., Brennan F., Vinen K., Davison S.N. An Approach to Pain Management in End Stage Renal Disease: Considerations for General Management and Intradialytic Symptoms. Semin. Dial. 2015; 28(4): 384–91. DOI: 10.1111/sdi.12372
  63. Kurella M., Bennett W., Chertow C. Analgesia in patients with ESRD: a review of available evidence. Am. J. Kidney Dis. 2003; 42(2): 217–228.
  64. Mathew R.O., Bettinger J.J., Wegrzyn E.L., Fudin J. Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease. J. Pain. Res. 2016; 8,9(12): 1191–1195.
  65. Kimmel P.L., Fwu C.W., Abbott K.C., et al. Opioid prescription, morbidity, and mortality in United States dialysis patients. J. Am. Soc. Nephrol. 2017; 28(12): 3658–3670. DOI: 10.1681/ASN.2017010098
  66. Desmet.C, Beguin C., Swine C., Jadoul M. Falls in hemodialysis patients: Prospective study of incidence, risk factors, and complications. Am. J. Kidney Dis. 2005; 45(1): 148–153.
  67. Ishida J.H., McCulloch C.E., Steinman M.A., et al. Opioid Analgesics and Adverse Outcomes among Hemodialysis Patients. Clin. J. Am. Soc. Nephrol. 2018; May 7; 13(5): 746–753. DOI: 10.2215/CJN.09910917
  68. Conway B.R., Fogarty D.G., Nelson W.E., Doherty C.C. Opiate toxicity in patients with renal failure. BMJ. 2006; 332: 345–346.
  69. Lee M.A., Leng M.E., Tiernan E.J. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat. Med. 2001; 15(1): 26–34. DOI: 10.1191/026921601669626431
  70. Conway B.R., Fogarty D.G., Nelson W.E., Doherty C.C. Opiate toxicity in patients with renal failure. BMJ. 2006; 332: 345–346. DOI: 10.1136/bmj.332.7537.345
  71. Filitz J., Griessinger N., Sittl R., et al. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur. J. Pain.2006; 10(8): 743–748. DOI: 10.1016/j.ejpain.2005.12.001
  72. Mordarski S. Efficacy and safety of buprenorphine in patients receiving haemodialysis. J. Appl. Ther. Res. 2009; 7: 46–51.
  73. Pham P.C., Khaing K., Sievers T.M., et al. 2017 update on pain management in patients with chronic kidney disease. Clin. Kidney J. 2017; 10 (5): 688–697.
  74. Dean M. Opioids in renal failure and dialysis patients. J. Pain Symptom Manage. 2004; 28(5): 497–504. DOI: 10.1016/j.jpainsymman.2004.02.021
  75. Baumgaertel M.W., Kraemer M., Berlit P. Neurologic complications of acute and chronic renal disease. Handb. Clin. Neurol. 2014; 119: 383–393. DOI: 10.1016/B978–0-7020-4086-3.00024–2
  76. Mambelli E., Barrella M., Facchini M.G., et al. The prevalence of peripheral neuropathy in hemodialysis patients. Clin/ Nephrol. 2012; 7796): 468–475.
  77. Boston A.G., Shemin D., Lapane К.L., et al. High dose B-vitamin treatment ot hyperhomocysteinemia in dialysis patients. Kidney Int. 1996; 49: 147–152.
  78. Ramírez B.V. Uraemic neuropathy. A review International Journal of Genetics and Molecular Biology. 2012; 3(11): 155–160.
  79. Warren D., Otieno L. Carpal tunnel syndrome in patients on intermittent haemodialysis. Postgrad. Med. J. 1975; 51(597): 450–452.
  80. Asencio G., Rigout C., Ramperez P., et al. Hemodialysis-related lesions of the hand. Rev Rhum Engl Ed. 1995; 62(4): 233–240.
  81. Nomoto Y., Kawaguchi Y., Ohira S., et al. Carpal Tunnel Syndrome in patients undergoing CAPD: a collaborative study in 143 centers. Am. J. Nephrol. 1995; 15(4): 295–299. DOI: 10.1159/000168852
  82. Kwon H.K., Pyun S.B., Cho W.Y., Boo C.S. Carpal tunnel syndrome and peripheral polyneuropathy in patients with end stage kidney disease. J. Korean. Med. 2011; 26(9): 1227–1230. DOI: 10.3346/jkms.2011.26.9.1227
  83. Nardin R., Chapman K., Raynor E. Prevalence of ulnar neuropathy in patients receiving hemodialysis. Arch. Neurol. 2005; 62(2): 271–275. DOI: 10.1001/archneur.62.2.271
  84. Naylor H., Raymond C. Treatment of neuropathic pain in patients with chronic kidney disease. CANNT. 2011; 21(1): 34–38.
  85. Biyik Z., Solak Y., Atalay H., et al. Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized rospective crossover trial. Int. Urol Nephrol. 2013; 45(3): 831–837. DOI: 10.1007/s11255-012-0193-1
  86. Atalay H., Solak Y., Biyik Z., et al. Crossover, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clin. Drug. Investig. 2013; 33(6): 401–408. DOI: 10.1007/s40261-013-0080-2
  87. Ishida J.H., McCulloch C.E., Steinman M.A., et al. Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients. J. Am. Soc. Nephrol. 2018; 29(7): 1970–1978. DOI: 10.1681/ASN.2018010096
  88. Zand L., McKian K., Qian Q. Gabapentin toxicity in patients with chronic kidney disease: a preventable cause or morbidity. Am. J. Med. 2010; 123(4): 367–373. DOI: 10.1016/j.amjmed.2009.09.030
  89. Beydoun A., Uthman B., Sackellares J. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol. 1995; 18(6): 469–481.
  90. Troy S., Shultz R., Parker V., et al. The effect of renal disease on the disposition of venlafaxine. Clin. Pharmacol. Ther. 1994; 56(1): 14–21.
  91. Lobo E., Heathman M., Kuan H., et al. Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine. Clin Pharmacokinet. 2010; 4995): 311–321. DOI: 10.2165/11319330-000000000-00000
  92. Marks J.L., van dH, Colebatch A.N., Buchbinder R., Edwards C.J. Pain pharmacotherapy in patients with inflammatory arthritis and concurrent cardiovascular or renal disease: a Cochrane systematic review. J. Rheumatol. 2012; 90: 81–84. DOI: 10.3899/jrheum.120347
  93. Hardouin P., Flipo R.M., Foissac-Gegoux P., et al. Dialysis-related beta 2 microglobulin-amyloid arthropathy. Improvement of clinical symptoms after a switch of dialysis membranes. Clin. Rheumatol. 1988; 7(1): 41–45.
  94. Shiota E., Tsuchiya K., Yamaoka K., Kawano O. Open carpal tunnel decompression in long-term haemodialysis patients. J. Hand. Surg. 2001; 2696: 529–532. DOI: 10.1054/jhsb.2000.0550
  95. Coleman S.H., Madsen M., Di Carlo E.F., et al. Arthroscopic synovectomy for the management of shoulder arthropathy in chronic renal dialysis patients. J Shoulder Elbow Surg. 2003; 12(2): 144–147. DOI: 10.1067/mse.2003.30

Chronical Pain Syndromes as a Critical Condition Consequence: Clinical Physiology, Diagnosis, Treatment

A.P. Spasova, V.V. Maltsev

Medical Institution of Petrozavodsk State University, Petrozavodsk

For correspondence: Spasova Arina Pavlovna — Candidate of Medical Science, Assistant Professor of Chair of X-Ray diagnostic and X-Ray treatment with course of Critical and Respiratory Medicine of Medical Institution of Petrozavodsk State University, Petrozavodsk; e-mail:

For citation: Spasova AP, Maltsev VV. Chronical Pain Syndromes as a Critical Condition Consequence: Clinical Physiology, Diagnosis, Treatment. Intensive Care Herald. 2017;4:19–28.

The review analyzes the prevalence of chronic pain syndromes in patients who have suffered a critical condition. The features of nociception processes and developing a sense of pain, the factors are analyzed to facilitate the transition of acute pain to chronic and possibility of their correction. Clinical and instrumental methods for the full evaluation of chronic pain syndrome, taking into account its specificity, as well as the basic principles of therapy, are considered.

Keywords: chronic pain, Post Intensive Care Syndrome, critical illness

Received: 25.10.2017


  1. Wunsch H., Angus D.C., Harrison D.A. et al. Variation in critical care services across North America and Western Europe. Care Med. 2008; 36: 2787–2793, e1. doi: 10.1097/ CCM.0b013e318186aec8.
  2. Zimmerman J.E., Kramer A.A., Knaus W.A. Changes in hospital mortality for United States intensive care unit admissions from 1988 to 2012. Crit. Care. 2013; 17: R81. doi: 1186/ cc12695.
  3. Brinkman S., Bakhshi-Raiez F., Abu-Hanna A. et al. Determinants of mortality after hospital discharge in ICU patients: Literature review and Dutch cohort Crit. Care Med. 2013; 41: 1237– 1251. doi: 10.1097/CCM.0b013e31827ca4f9.
  4. Dowdy D.W., Eid M.P., Sedrakyan A. et al. Quality of life in adult survivors of critical illness: A systematic review of the literature. Intensive Care Med. 2005; 31: 611–620. doi: 10/1007/s00134- 005-2592-6.
  5. Rosendahl J., Brunkhorst F.M., Jaenichen D. et al. Physical and mental health in patients and spouses after intensive care of severe sepsis: A dyadic perspective on long-term sequelae testing the Actor-Partner Interdependence Model. Care Med. 2013; 41: 69–75. doi: 10.1097/CCM.0b013e31826766b0.
  6. Needham D.M., Davidson J., Cohen H. et al. Improving long-term outcomes after discharge from intensive care unit: Report from a stakeholders’ Crit. Care Med. 2012; 40: 502– 509. doi: 10.1097/CCM.0b013e318232da75.
  7. Davydow D.S., Katon W.J., Zatzick D.F. Psychiatric morbidity and functional impairments in survivors of burns, traumatic injuries, and ICU stays for other critical illnesses: A review of the literature. Int. Psychiatry. 2009; 21: 531–538. doi: 10.3109/09540260903343877.
  8. Iwashyna T.J., Ely E.W., Smith D.M. et al. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010; 304: 1787–1794. doi: 10.1001/ jama.2010.1553.
  9. Wolters A.E., Slooter A.J., van der Kooi A.W. et al. Cognitive impairment after intensive care unit admission: A systematic review. Care Med. 2013; 39: 376–386. doi: 10.1007/s00134- 012-2784-9.
  10. Herridge M.S., Tansey C.M., Matté A. et al. Canadian Critical Care Trials Group: Functional disability 5 years after acute respiratory distress N. Engl. J. Med. 2011; 364: 1293–1304. doi: 10.1056/NEJMoa1011802.
  11. Erstad B.L., Puntillo K., Gilbert H.C., Grap M.J., Li D., Medi- na J. et al. Pain management principles in the critically Chest. 2009, 135: 1075–1086. doi: 10.1378/chest.08-2264.
  12. Stanik-Hutt J.A., Soeken K.L., Belcher A.E. et al. Pain experiences of traumatically injured patients in a critical care setting. Am. J. Crit. Care. 2001; 10: 252–259.
  13. Nelson J.E., Meier D.E., Oei E.J., Nierman D.M., Sen- zel R.S. et al. Self-reported symptom experience of critically ill cancer patients receiving intensive care. Crit. Care. Med. 2001; 29: 277–282. doi: 1097/00003246-200102000-00010.
  14. Овечкин А.М. Хронический послеоперационный болевой синдром — подводный камень современной хирургии. Регионарная анестезия и лечение острой боли. 2016; 10(1): 5–18. [Ovechkin A.M. Chronic postoperative pain syndrome — “a pit- fall” of modern surgery. Regionarnaya anesteziya i lechenie ostroj 2016; 10(1): 5–18. (in Russ)]. doi: 10.18821/19936508-2016-10-1-5-18.
  15. Овечкин А.М., Политов М.Е., Панов Н.В. Острый и хронический болевой синдром у пациентов, перенесших тотальное протезирование суставов нижних конечностей. Анестезиология и реаниматология. 2017; 62(3): 224–230. [Ovechkin A.M., Politov M.E., Panov N.V. Acute and chronic pain syndrome after total hip and knee Anesteziologiya i reanimatologi- ya, 2017, 62(3): 224–230. (in Russ)]. doi: 10.18821/0201-7563- 2017-62-3-224-230.
  16. Chanques G., Sebbane M., Barbotte E., Viel E., Eledjam J.J., Jaber S. A prospective study of pain at rest: Incidence and characteristics of an unrecognized symptom in surgical and trauma versus medical intensive care unit Anesthesiology. 2007; 107: 858–860. doi: 10.1097/01.anes.0000287211.98642.51.
  17. Gelinas C., Fillion L., Puntillo K.A., Viens C., Fortier M. Validation of the critical care pain observation tool in adult patients. Am. J. Crit. Care. 2006; 15: 420–427.
  18. Payen J.F., Bru O., Bosson J.L., Lagrasta A., Novel E., Deschaux I. et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. Care Med. 2001; 29: 2258–2263. doi: 10.1097/00003246-200112000-00004.
  19. Gelinas C. Management of pain in cardiac surgery ICU patients: Have we improved over time? Intensive Crit. Care Nurs. 2007; 23: 298–303. doi: 1016/j.iccn.2007.03.002.
  20. Jones J., Hoggart B., Withey J. et al. What the patients say: a study of reactions to an intensive care unit. Intensive Care Med. 1979; 5: 89–92.
  21. Schelling G., Richter M., Roozendaal B. et al. Exposure to high stress in the intensive care unit may have negative effects on health-related quality-of-life outcomes after cardiac sur Crit. Care Med. 2003; 31: 1971–1980. doi: 10.1097/01. CCM.0000069512.10544.40.
  22. Dowdy D.W., Eid M.P., Dennison C.R., Mendez-Tellez P.A., Herridge M.S. et al. Quality of life after acute respiratory distress syndrome: a meta-analysis. Intensive Care 2006, 32: 1115–1124. doi: 10.1007/s00134-006-0217-3.
  23. Der Schaaf M., Beelen A., Dongelmans D., Vroom M., Nollet F. Poor functional recovery after critical A longitudinal study. J. Rehab. Med. 2009; 41: 1041–1048. doi: 10.2340/16501977- 0443.
  24. Pavoni V., Gianesello L., Paparella L., Buoninsegni L.T., Barboni E. Outcome predictors and quality of life of severe burn patients admitted to intensive care unit. Scand. J. Trauma Resusc. Emerg. Med. 2010; 18: 24–32. doi: 10.1186/1757-7241- 18-24.
  25. Cuthbertson B.H., Roughton S., Jenkinson D., MacLennan G., Vale L. Quality of life in the five years after intensive care: a cohort study. Crit. Care. 2010; 14: R6. doi: 1186/cc8848.
  26. Timmers T.K., Verhofstad M.H., Moons K.H. et al. Long-term quality of life after surgical intensive care Arch. Surg. 2011; 146: 412–418. doi: 10.1001/archsurg.2010.279.
  27. Zimmer A., Rothaug J., Mescha S., Reinhart K., Meissner W., Marx G. Chronic pain after surviving sepsis. Care. 2006; 10(Suppl 1): P421. doi: 10.1186/cc4768.
  28. Jose G.M. H., Spronk P.E., van Stel H.F., Schrijvers G.J.P., Rommes J.H., Jan Bakker J. The impact of critical illness on perceived health-related quality of life during ICU treatment, hospital stay, and after hospital discharge: a long-term follow-up study. Chest. 2008; 133: 377–385. doi: 1378/chest.07-1217.
  29. McMahon S.B., Bennett D.L.H., Bevan S. Inflammatory mediators and modulators of pain. In Wall and Melzackʼs Textbook of Pain. Eds.: S.B McMahon, M. Koltzenburg. Philadelphia: Elsevier, 2008: 49–72.
  30. Ritner H.L., Machelska H., Stein C. Immune system pain and analgesia. In Science of Pain. Eds.: A.I. Bausbaum, M. Oxford, England: Academic Press, 2009: 407–427. doi:10.1186/2110-5820-2-36.
  31. Lindenlaub T., Teuteberg P., Hartung T., Sommer C. Effects of neutralizing antibodies to TNF-alpha on pain-related be- havior and nerve regeneration in mice with chronic constriction injury. Brain Res. 2000; 866: 15–22. doi: 10.1016/S0006-8993(00)02190-9.
  32. Twining C.M., Sloane E.M., Milligan E.D., Chacur M., Mar- tin D. et al. Peri-sciatic proinflammatory cytokines, reactive oxygen species, and complement induce mirror-image neuropathic pain in Pain. 2004; 110: 299–309. doi: 10.1016/j.pain.2004.04.008.
  33. Cui J.G., Holmin S., Mathiesen T., Meyerson B.A., Linderoth B. Possible role of inflammatory mediators in tactile hypersensitivity in rat models of mononeuropathy. Pain. 2000; 88: 239–248. doi: 1016/S0304-3959(00)00331-6.
  34. Liu T., van Rooijen N., Tracey D.J. Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve Pain. 2000; 86: 25–32. doi: 10.1016/S0304- 3959(99)00306-1.
  35. Hynninen M.S., Cheng D.C., Hossain I., Carroll J., Aumbhaga- van S.S., Yue R. et al. Non-steroidal anti-inflammatory drugs in treatment of postoperative pain after cardiac surgery. Can. J. Anaesth. 2000; 47: 1182–1187. doi: 1007/BF03019866.
  36. Woolf C.J. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011; 152(3 Suppl): S2–S15. doi: 1016/j.pain.2010.09.030.
  37. Watkins L.R., Maier S.F. Beyond neurons: Evidence that immune and glial cells contribute to pathological pain Physiol. Rev. 2002; 82: 981–1011. doi: 10.1152/physrev.00011.2002.
  38. Hu P., McLachlan E.M. Macrophage and lymphocyte invasion of dorsal root ganglia after peripheral nerve lesions in the rat. 2002; 112: 23–38. doi: 10.1016/S0306– 4522(02)00065–9.
  39. Morioka N., Inoue A., Hanada T., Kumagai K., Takeda K., Ikoma K. et al. Nitric oxide synergistically potentiates interleukin-1 beta-induced increase of cyclooxygenase-2 mRNA levels, resulting in the facilitation of substance P release from primary afferent neurons: involvement of cGMP independent mechanisms. Neuropharmacology. 2002; 43: 868–876. doi: 10.1016/ S0028-3908(02)00143-0.
  40. Hou L., Li W., Wang X. Mechanism of interleukin-1 beta-induced calcitonin gene-related peptide production from dorsal root ganglion neurons of neonatal rats. J. Neurosci. Res. 2003; 73: 188–197. doi: 1002/jnr.10651.
  41. Latremoliere A., Woolf C.J. Central sensitization: A generator of pain hypersensitivity by central neural J. Pain. 2009; 10: 895–926. doi: 10.1016/j.jpain.2009.06.012.
  42. Pandey C.K., Bose N., Garg G., Singh N., Baronia A., Agar- wal A. et al. Gabapentin for the treatment of pain in Guillain-Barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesth. Analg. 2002; 95: 1719–1723. doi: 1097/00000539-200212000-00046.
  43. Pandey C.K., Raza M., Tripathi M., Navkar D.V., Kumar A., Singh U.K. The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care Anesth. Analg. 2005; 101: 220–225. doi: 10.1213/01.ANE.0000152186.89020.36.
  44. Joly V., Richebe R., Guignard B., Fletcher D., Maurette P., Sessler D.I. et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. 2005; 103: 147–155. doi: 10.1097/00000542- 200507000-00022.
  45. Goshgarian H. Anatomy and function of the spinal cord. In: Spinal Cord Medicine: Principles and Eds.: W.L. Vernon, D.D. Cardenas, N.C. Cutter, F.S. Frost, M.C. Hammond, L.B. Lindblom, I. Perkash, R. Waters, R.M. Woolsey. New York: Demos Medical Publishing, 2003: 15–35.
  46. Sandkuhler J. Models and mechanisms of hyperalgesia and allodynia. Physiol. 2009; 89: 707–758. doi: 10.1152/ physrev.00025.2008.
  47. Lee J.W., Siegel S.M., Oaklander A.L. Effects of distal nerve injuries on dorsal-horn neurons and glia: Relationships between lesion size and mechanical hyperalgesia. 2009; 158: 904–914. doi: 10.1016/j.neuroscience.2008.10.010.
  48. Millan M.J. Descending control of pain. Neurobiol. 2002; 66: 355–474. doi: 10.1016/S0301-0082(02)00009-6.
  49. Neumann S., Doubell T.P., Leslie T., Woolf C.J. Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature. 1996; 384: 360–364. doi: 1038/384360a0.
  50. Cherubini E., Conti F. Generating diversity at GABAergic synapses. Trends Neurosci. 2001; 24: 155–162. doi: 10.1016/ S0166-2236(00)01724-0.
  51. Luo C., Seeburg P.H., Sprengel R., Kuner R. Activity-dependent potentiation of calcium signals in spinal sensory networks in inflammatory pain states. 2008; 140: 358–367. doi: 10.1016/j.pain.2008.09.008.
  52. Porreca F., Ossipov M.H., Gebhart G.F. Chronic pain and medullary descending facilitation. Trends Neurosci. 2002; 25: 319–325. doi: 1016/S0166-2236(02)02157-4.
  53. Urban M.O., Gebhart G.F. Supraspinal contributions to hyperalgesia. Proc. Acad. Sci USA. 1999; 96: 7687– 7692. doi: 10.1073/pnas.96.14.7687.
  54. Watkins L.R., Maier S.F. Implications of immune-to-brain communication for sickness and Proc. Natl. Acad. Sci USA. 1999; 96: 7710–7713. doi: 10.1073/pnas.96.14.7710.
  55. Marcuzzi A., Wrigley P.J., Dean C.M, Adams R., Hush J.M. The long-term reliability of static and dynamic quantitative sensory testing in healthy individuals. 2017; 158: 1217– 1223. doi: 10.1097/j.pain.0000000000000901.
  56. Mattia C., Savoia G., Paoletti F., Piazza O., Albanese D., Amantea B. et al. SIAARTI recommendations for analgo- sedation in intensive care unit. Minerva Anestesiol. 2006; 72: 769–805.
  57. Chanques G., Sebbane M., Constantin J.M., Ramillon N., Jung B., Cisse M., Lefrant J.Y., Jader S. Analgesic efficacy and haemodynamic effects of nefopam in critically ill patients. J. Anaesth. 2011; 106: 336–343. doi: 10.1093/bja/aeq375.
  58. Fields H.L., Heinricher M.M. Anatomy and physiology of a nociceptive modulatory system. Philos. Trans. R. Soc. Lond B. Biol. Sci. 1985; 308: 361–374. doi: 10.1098/ rstb.1985.0037.
  59. Porreca F., Burgess S.E., Gardell L.R., Vanderah T.W., Malan T.P.Jr., Ossipov M.H. et al. Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor. Neurosci. 2001; 21: 5281–5288.
  60. Milligan E.D., Twining C., Chacur M., Biedenkapp J., OʼConnor K., Poole S. et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. Neurosci. 2003; 23: 1026–1040.
  61. Watkins L.R., Wiertelak E.P., Furness L.E., Maier S.F. Illness- induced hyperalgesia is mediated by spinal neuropeptides and excitatory amino acids. Brain. Res. 1994; 664: 17–24. doi: 1016/0006-8993(94)91948-8.
  62. Watkins L.R., Maier S.F. Glia: a novel drug discovery target for clinical pain. Nat. Drug. Discov. 2003; 2: 973–985. doi: 10.1038/nrd1251.
  63. Ren K., Dubner R. Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Opin. Anaesthesiol. 2008; 21: 570–579. doi: 10.1097/ACO.0b013e32830edbdf.
  64. Quan N., Herkenham M. Connecting cytokines and brain: a review of current issues. Histol. Histopathol. 2002; 17: 273– 288.
  65. Romeo H.E., Tio D.L., Rahman S.U., Chiappelli F., Taylor A.N. The glossopharyngeal nerve as a novel pathway in immune-to- brain communication: Relevance to neuroimmune surveillance of the oral cavity. Neuroimmunol. 2001; 115: 91–100. doi: 10.1016/S0165-5728(01)00270-3.
  66. Watkins L.R., Maier S.F., Goehler L.E. Cytokine-to-brain communication: a review and analysis of alternative mechanisms. Life 1995; 57: 1011–1026. doi: 10.1016/0024- 3205(95)02047-M.
  67. Constandil L., Hernandez A., Pelissier T., Arriagada O., Espinoza K., Burgos H. et al. Effect of interleukin-1beta on spinal cord nociceptive transmission of normal and monoarthritic rats after disruption of glial function. Res. Ther. 2009; 11: R105. doi: 10.1186/ar2756.
  68. Reeve A.J., Patel S., Fox A., Walker K., Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. J. Pain (London, Engl.). 2000; 4: 247–257. doi: 10.1053/eujp.2000.0177.
  69. Watkins L.R., Martin D., Ulrich P., Tracey K.J., Maier S.F. Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. 1997; 71: 225– 235. doi: 10.1016/S0304-3959(97)03369-1.
  70. de Goeij M., van Eijk L.T., Vanelderen P. et al. Systemic inflammation decreases pain threshold in humans in vivo. PLoS One. 2013; 8: e84159. pone.0084159.
  71. Price D.D. Psychological and neural mechanisms of the affective dimension of pain. Science (New York). 2000; 288: 1769–1772.
  72. Craig A.D. Interoception: The sense of the physiological condition of the Curr. Opin. Neurobiol. 2003; 13: 500–505.
  73. Apkarian A.V., Bushnell M.C., Treede R.D., Zubieta J.K. Human brain mechanisms of pain perception and regulation in health and disease. J. Pain (London, Engl.). 2005; 9: 463–484. doi: 10.1016/j.ejpain.2004.11.001.
  74. Zhang L., Zhang Y., Zhao Z.Q. Anterior cingulate cortex contributes to the descending facilitatory modulation of pain via dorsal reticular nucleus. J. Neurosci. 2005; 22: 1141– 1148. doi: 10.1111/j.1460-9568.2005.04302.x.
  75. Jacodic H.K., Jakodic K., Podbregar M. Long-term outcome and quality of life of patients treated in a surgical intensive care: a comparison between sepsis and trauma. Care. 2006; 10: R134. doi: 10.1186/cc5047.
  76. Tanji J., Hoshi E. Behavioral planning in the prefrontal cortex. Opin. Neurobiol. 2001; 11: 164–170. doi: 10.1016/S0959- 4388(00)00192-6.
  77. Daw N.D., OʼDoherty J.P., Dayan P., Seymour B., Dolan R.J. Cortical substrates for exploratory decisions in Nature. 2006; 441: 876–879. doi: 10.1038/nature04766.
  78. Apkarian A.V. Pain perception in relation to emotional learning. Opin. Neurobiol. 2008; 18: 464–468. doi: 10.1016/j. conb.2008.09.012.
  79. Brosschot J.F., Gerin W., Thayer J.F. The perseverative cognition hypothesis: a review of worry, prolonged stress-related physiological activation, and health. J. Psychosom. Res. 2006; 60: 113–124. doi: 1016/j.jpsychores.2005.06.074.
  80. Siffleet J., Young J., Nikoletti S., Shaw T. Patientsʼ self-report of procedural pain in the intensive care J. Clin. Nurs. 2007; 16: 2142–2148. doi: 10.1111/j.1365-2702.2006.01840.x.
  81. Young J., Siffleet J., Nikoletti S., Shaw T. Use of a behavioural pain scale to assess pain in ventilated, unconscious and/or sedated patients. Intensive Crit. Care. Nurs. 2006; 22: 32–39. doi: 1016/j.iccn.2005.04.004.
  82. Neugebauer V., Li W., Bird G.C., Han J.S. The amygdala and persistent pain. Neuroscientist. 2004; 10: 221–234. doi: 1177/1073858403261077.
  83. Zhuo M. A synaptic model for pain: long-term potentiation in the anterior cingulate cortex. Mol. Cells. 2007; 23: 259–271.
  84. Izard C.E. Emotion theory and research: highlights, unanswered questions, and emerging Annual Rev. Psychol. 2009; 60: 1–25. doi: 10.1146/annurev.psych.60.110707.163539.
  85. Bruce J., Quinlan J. Chronic post-surgical pain. J. Pain. 2011; 5: 23–29. doi: 10.1177/204946371100500306.
  86. Baumbach P., Gotz T., Gunther A., Weiss T., Meissner W. Prevalence and characteristics of chronic intensive care-related pain: the role of severe sepsis and septic Crit. Care. Med. 2016; 44: 1129–1137. doi: 10.1097/CCM.0000000000001635.
  87. Puntillo K., Naidu R. Chronic pain disorders after critical illness and ICU-acquired opioid dependence: two clinical conun- dra. Opin. Crit. Care. 2016; 22: 506–512. doi: 10.1097/ MCC.0000000000000343.
  88. Fletcher D., Stamer U.M., Pogatzki-Zahn E., Zaslansky R., Ta- nase N.V. et al.; euCPSP group for the Clinical Trial Network group of the European Society of Chronic post- surgical pain in Europe: an observational study. Eur. J. Anaesthe- siol. 2015; 32: 725–734. doi: 10.1097/EJA.0000000000000319.
  89. Puntillo K.A., Max A., Timsit J.F. et al. Determinants of procedural pain intensity in the intensive care The Europain(R) study. Am. J. Respir Crit. Care. Med. 2014; 189: 39–47. doi: 10.1164/ rccm.201306-1174OC.
  90. Salanova M., Gelfi C., Moriggi M., Vasso M., Viganò A., Minafra L. et al. Disuse deterioration of human skeletal muscle challenged by resistive exercise superimposed with vibration: evidence from structural and proteomic analysis. FASEB J. 2014; 28(11): 4748–4763. doi: 1096/fj.14-252825.
  91. Clavet H., Hébert P.C., Fergusson D., Doucette S., Trudel G. Joint contracture following prolonged stay in the intensive care unit. 2008; 178(6): 691–697. doi: 10.1503/cmaj.071056.
  92. Bekkering G.E., Bala M.M., Reid K., Kellen E., Harker J., Riems- ma R., Huygen F.J., Kleijnen J. Epidemiology of chronic pain and its treatment in the Netherlands. J Med. 2011; 69: 141–153.
  93. Badcock L.J., Lewis M., Hay E.M., McCarney R., Croft P.R. Chronic shoulder pain in the community: a syndrome of disability or distress? Rheum. Dis. 2002; 61: 128–131. doi: 10.1136/ ard.61.2.128.
  94. Breivik H., Collett B., Ventafridda V., Cohen R., Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life and treatment. J. Pain. 2006; 10: 287–333. doi: 10.1016/j. ejpain.2005.06.009.
  95. Gustafson O. The incidence of shoulder dysfunction in ICU sur- vivors [Abstract]. doi: 1186/cc12746.
  96. Labriola J.E., Lee T.Q., Debski R.E., McMahon P.J. Stability and instability of the glenohumeral joint: the role of shoulder J. Shoulder. Elbow. Surg. 2005, 14: 32–38. doi: 10.1016/j.jse.2004.09.014.
  97. Devine H., MacTavish P., McPeake J., Quasim T., Kinsella J., Daniel M. Musculoskeletal problems in intensive care unit (ICU) patients post-discharge. Care. 2016; 20(Suppl 2): P414.
  98. Latronico N., Filosto M., Fagoni N. et al. Small nerve fiber pathology in critical illness. PLoS One. 2013; 8: e75696. doi. org/10.1371/journal.pone.0075696.
  99. Skorna M., Kopacik R., Vlckova E. et al. Small-nerve-fiber pathology in critical illness documented by serial skin biopsies. Muscle Nerve. 2015; 52: 28–33. doi: 1002/mus.24489.
  100. Backonja M.M., Attal N., Baron R. et al. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. 2013; 154: 1807–1819. doi: 10.1016/j. pain.2013.05.047.
  101. Lin M.T., Lee L.J., Chao C.C. et al. Quality of life in polyneuropathy: Association with biomarkers of small fiber impairment. Health Qual Life 2015; 13: 169. doi: 10.1186/s12955- 015-0363-9.
  102. Royal College of Physicians, British Geriatrics Society and British Pain The assessment of pain in older people: nation- al guidelines: concise guidance to good practice series. № 8. London: RCP, 2007.
  103. Connolly B., Salisbury L., O’Neill B. et al. Exercise rehabilitation following intensive care unit discharge for recovery from critical illness. Cochrane Database Syst. 2015; 6: CD008632. doi: 10.1002/14651858.CD008632.pub2.
  104. National Institute for Clinical Excellence: CG83: Critical Illness Rehabilitation: Guideline. URL: 12137/58250/58250.pdf.